Mahi Drugs is an API manufacturer based in India. It holds 10 active US drug master files across a filed portfolio of 10 molecules. Customs aggregates show $615K of exports covering 14 molecules to 8 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Anakapalli, India | 3019853340 |
| Molecule | Regulators | Docs |
|---|---|---|
| Albendazole | US FDA | 1 |
| Aprepitant | US FDA | 1 |
| Bupropion | US FDA | 1 |
| Famotidine | US FDA | 1 |
| Fosaprepitant | US FDA | 1 |
| Hydroxyzine | US FDA | 1 |
| Mirtazapine | US FDA | 1 |
| Nicardipine | US FDA | 1 |
| Pregabalin | US FDA | 1 |
| Trazodone | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $284K | 2 |
| 2025 | Not reported | $615K | 8 |
| 2024 | Not reported | $285K | 4 |
| 2023 | Not reported | $45K | 2 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Mahi Drugs comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.